Latest & greatest articles for donepezil

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on donepezil or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on donepezil and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for donepezil

61. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review

Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review Journals Library Journals Library An error has occurred in processing the XML document An error has occurred in processing the XML document An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose

NIHR HTA programme2000

62. Donepezil for mild and moderate Alzheimer's disease.

Donepezil for mild and moderate Alzheimer's disease. BACKGROUND: Alzheimer's disease is the most common cause of dementia and is a primary degenerative disease of the brain of unknown cause. Onset is usually late in life with increasing impairment of memory, developing gradually into a global impairment of cognition, orientation, linguistic ability and judgement. The clinical course is accompanied by growing disability and dependency on care. One of the characteristic features of the disease (...) in this way, but caused severe side effects. E2020 (donepezil, Aricept) is a second generation cholinesterase inhibitor and appears to be highly specific, with relatively few side effects. OBJECTIVES: The objective of this review is to assess whether or not donepezil improves the well-being of patients with mild or moderate Alzheimer's disease. SEARCH STRATEGY: The Cochrane Dementia and Cognitive Impairment Group Register of Clinical Trials, was searched using the terms 'donepezil', 'E2020' and 'ARICEPT

Cochrane2000

63. Donepezil for mild and moderate Alzheimer's disease.

Donepezil for mild and moderate Alzheimer's disease. BACKGROUND: Alzheimer's disease is the most common cause of dementia in older people. One of the aims of therapy is to inhibit the breakdown of a chemical neurotransmitter, acetylcholine, by blocking the relevant enzyme. This can be done by a group of chemicals known as cholinesterase inhibitors. However, some (like tacrine) are associated with adverse effects such as hepatotoxicity, but E2020 (donepezil, Aricept) is thought to be more (...) specific in its action, and safer. OBJECTIVES: The objective of this review is to assess whether or not donepezil improves the well-being of patients with mild or moderate Alzheimer's disease. SEARCH STRATEGY: The Cochrane Dementia and Cognitive Improvement Group specialized register was searched using the terms 'donepezil', 'E2020' and 'Aricept'. Members of the Donepezil Study Group and Eisai Inc were contacted. SELECTION CRITERIA: All unconfounded, double-blind, randomized controlled trials in which

Cochrane2000

64. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease

Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease Neumann P J, Hermann R C, Kuntz K M, Araki S S, Duff S B, Leon J, Berenbaum P A, Goldman P A, Williams L W, Weinstein M C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Donepezil was compared with no pharmacological treatment for the management of mild to moderate Alzheimer's disease. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study modelled the impact of donepezil for a patient population

NHS Economic Evaluation Database.1999

65. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada

Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada O'Brien B J, Goeree R, Hux M, Iskedjian M, Blackhouse G, Gagnon M, Gauthier S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of an anti-dementia drug, donepezil to slow the progression of dementia in patients with mild or moderate Alzheimer's Disease (AD). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Individuals with probable mild or moderate Alzheimer's Disease (Mini-Mental Health State Examination (MMSE

NHS Economic Evaluation Database.1999

66. Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil

Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil Stewart A, Phillips R, Dempsey G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health technology studied was donepezil, a piperidine-based derivative used for the treatment of patients suffering from Alzheimer disease (AD). Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised

NHS Economic Evaluation Database.1998

67. Donepezil in the treatment of mild to moderate senile dementia of the Alzheimer type (SDAT)

Donepezil in the treatment of mild to moderate senile dementia of the Alzheimer type (SDAT) Donepezil in the treatment of mild to moderate senile dementia of the Alzheimer type (SDAT) Donepezil in the treatment of mild to moderate senile dementia of the Alzheimer type (SDAT) Stein K Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Stein K (...) . Donepezil in the treatment of mild to moderate senile dementia of the Alzheimer type (SDAT) Southampton: Wessex Institute for Health Research and Development (WIHRD) 1997 Authors' objectives Donepezil is a new drug treatment, recently licensed in the UK, for use in mild to moderate dementia due to senile dementia of the Alzheimer type (SDAT). The author assesses whether it should be made available to all patients with mild to moderate SDAT. Authors' conclusions The effectiveness of donepezil in routine

Health Technology Assessment (HTA) Database.1997